Keeping Current

521 Folgen

1. New Considerations in Managing Family Planning in Multiple Sclerosis

   Vom: 8.5.2025
2. Advancing Precision Oncology: Recent Progress and Future Outlook

   Vom: 1.5.2025
3. Advanced HER2-Positive Gastric/GEJ Cancers: Expert Insights on Current and Future Strategies

   Vom: 30.4.2025
4. Decoding PD-L1 Scoring: Guiding Immunotherapy for Gastroesophageal Cancers

   Vom: 29.4.2025
5. Patient-Centered Paroxysmal Nocturnal Hemoglobinuria Treatment & the Role of Terminal Complement Inhibitors

   Vom: 31.3.2025
6. Are We Undertreating Depression in People Living With Epilepsy?

   Vom: 31.3.2025
7. Pearls on Retina Biomarkers for Clinical Practice

   Vom: 28.3.2025
8. Sharing Expert Minds in Lung Cancer and Lung Neuroendocrine Tumors Delivering Optimal Patient Care

   Vom: 20.3.2025
9. COVID-19 Antivirals: Real-World Evidence Review

   Vom: 18.3.2025
10. Should We Be Thinking More About Bile Acids in Progressive Cholestatic Liver Diseases?

    Vom: 14.3.2025
11. A Year in Review of Antibody-Drug Conjugates for Breast Cancer: Trends, Practice, and Outlook

    Vom: 28.2.2025
12. Unveiling the Invisible: The Acute and Chronic Burden of Respiratory Syncytial Virus Disease

    Vom: 28.2.2025
13. How I Treat Advanced Hepatocellular Carcinoma: Mastering Immunotherapy for Optimal Outcomes

    Vom: 13.2.2025
14. Interdisciplinary Dialogue: A Cardiologist's Guide to Evidence-Based Obesity Care

    Vom: 12.2.2025
15. Latest Advances in Breast Cancer: Essential Highlights From San Antonio 2024

    Vom: 31.1.2025
16. Shaping the Future of Advanced Breast Cancer Care: A Deep Dive Into Novel Data and Emerging Therapies

    Vom: 29.1.2025
17. The Great Debate: Is Seizure Freedom Always Achievable in Focal Epilepsy?

    Vom: 24.1.2025
18. Advancing Precision Cancer Medicine: Unveiling the Future Frontier

    Vom: 23.1.2025
19. Lack of Adherence to Basal Insulin: Are Once-Weekly Formulations the Solution?

    Vom: 22.1.2025
20. COVID-19 and Oral Antivirals: How to Define an Eligible Patient

    Vom: 3.1.2025